



## Pharmacotherapy of Central Serous Chorioretinopathy

Guest Editor:

**Dr. Pierluigi Iacono**  
IRCCS Fondazione G.B. Bietti,  
Rome, Italy

Deadline for manuscript  
submissions:  
**closed (30 September 2020)**

### Message from the Guest Editor

Dear Colleagues,

Central serous chorioretinopathy (CSC) is one of the most common retinal disorders that ophthalmologists have to deal with. It may represent a real challenge due to a complex pathogenesis, as well as for the wide spectrum of clinical presentation through which it may begin. In addition, classification and its therapeutic approach are intriguing aspects.

This Special Issue aims to offer an update on the new CSC classification; a thorough description of the retinal morphological features that can be obtained with the most recent imaging methods; and finally and maybe above all, a critical review on the most common therapeutic options, namely photodynamic therapy with verteporfin, sub-threshold laser treatment and therapy with diuretics. We will be glad to receive a contribution from anyone wishing to bring personal experiences on all topics covered in this Special Issue.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)